Today's story
Acadia expects Rett drug protection through 2041
Trofinetide U.S. protection expected through March 28, 2041—nearly five years past the July 2036 method-of-use patent—after USPTO allowance for weight-banded dosing.
Health · 7 sources · 4dRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Trofinetide
Trofinetide, sold under the brand name Daybue among others, is a medication used for the treatment of Rett syndrome. It is taken by mouth.
Everything about Trofinetide →